You Lü

机构：Tulane University, LSU New Orleans, Chengdu Medical College, Sichuan University, Suzhou University of Science and Technology, West China Hospital of Sichuan University, Sichuan Cancer Hospital, Jiangsu Cancer Hospital, Baton Rouge Clinic, Nanjing Medical University · ORCID：0000-0003-1671-1408

发表论文 432 篇 · 总被引 12523 次 · h-index 53

代表论文

• Fecal microbiota transplantation plus immune checkpoint inhibitor rechallenges in patients with advanced non-small cell lung cancer: a single-arm exploratory study (2025 · Translational Lung Cancer Research · 被引 9)
• AdvanTIG-204: A Phase 2, Randomized, Open-Label Study of Ociperlimab Plus Tislelizumab and Concurrent Chemoradiotherapy Versus Tislelizumab and Concurrent Chemotherapy Versus Concurrent Chemoradiotherapy in First-Line Limited-Stage SCLC (2025 · JTO Clinical and Research Reports · 被引 3)
• Real-world use of and clinical outcomes with dacomitinib as first-line therapy in Asian patients with EGFR mutation–positive locally advanced or metastatic non-small cell lung cancer: Final analysis of the ARIA study (2025 · Lung Cancer · 被引 2)
• USP32 facilitates tumor development and is correlated with poor clinical outcomes in hepatocellular carcinoma patients and is modulated by the E2F7/miR-218-5p axis (2025 · LabMed discovery. · 被引 2)
• Efficacy of regorafenib following first-line immune checkpoint inhibitor failure in patients with advanced hepatocellular carcinoma: A multicenter study (2025 · Hepatobiliary & pancreatic diseases international · 被引 2)
• Integrated metabolome and transcriptome analysis revealed the mechanism of secondary metabolite biosynthesis in Bletilla striata under UV-C treatment (2025 · Plant Physiology and Biochemistry · 被引 1)